P68. A new EGFR - EpCAM bispecific antibody enhances the efficacy of adoptive T-cell therapy in a murine gastric tumour model

Kobold, S; Steffen, J; Grassmann, S; Castoldi, R; Schmollinger, J; Sustmann, C; Nierderfellner, G; Klein, C; Bourquin, Carole; Endres, S

doi:10.1186/2051-1426-2-s2-p42

Scientific article

English

P68. A new EGFR - EpCAM bispecific antibody enhances the efficacy of adoptive T-cell therapy in a murine gastric tumour model

ContributorsKobold, S; Steffen, J; Grassmann, S; Castoldi, R; Schmollinger, J; Sustmann, C; Nierderfellner, G; Klein, C; Bourquin, Carole

; Endres, S

Published inJournal for immunotherapy of cancer, vol. 2, no. S2

Publication date2014-03-12

First online date2014-03-12

Abstract

A limiting step for adoptively transferred tumour-specific T cells is their recruitment from the blood circulation to the proximity of tumour cells and subsequent engage- ment in direct tumour cell contact. We hypothesised that a bispecific antibody recruiting T cells to a target antigen on tumour cells could enhance T-cell-tumour interaction and thus increase the efficacy of adoptively transferred T cells

Affiliation entities

Not a UNIGE publication

Citation (ISO format)

KOBOLD, S et al. P68. A new EGFR - EpCAM bispecific antibody enhances the efficacy of adoptive T-cell therapy in a murine gastric tumour model. In: Journal for immunotherapy of cancer, 2014, vol. 2, n° S2. doi: 10.1186/2051-1426-2-s2-p42

Article (Published version)

CC BY

Identifiers

PID : unige:184300
DOI : 10.1186/2051-1426-2-s2-p42

Additional URL for this publicationhttps://jitc.bmj.com/lookup/doi/10.1186/2051-1426-2-S2-P42

Journal ISSN2051-1426

28views

40downloads

Creation16/10/2024 14:13:46

First validation04/04/2025 10:29:47

Update04/04/2025 10:29:47

Status update04/04/2025 10:29:47

Last indexation04/04/2025 10:29:48

Archive ouverte UNIGE

P68. A new EGFR - EpCAM bispecific antibody enhances the efficacy of adoptive T-cell therapy in a murine gastric tumour model

Technical informations